125 related articles for article (PubMed ID: 20098293)
1. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
[No Abstract] [Full Text] [Related]
2. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
3. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
[TBL] [Abstract][Full Text] [Related]
4. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
[TBL] [Abstract][Full Text] [Related]
5. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
Wang SS; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Ko WJ; Tsao CI; Sun CD
Transplant Proc; 2008 Oct; 40(8):2607-8. PubMed ID: 18929814
[TBL] [Abstract][Full Text] [Related]
6. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
[TBL] [Abstract][Full Text] [Related]
7. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
8. Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients.
Schweiger M; Stiegler P; Puntschart A; Sereinigg M; Prenner G; Wasler A; Tscheliessnigg K
Exp Clin Transplant; 2012 Jun; 10(3):273-7. PubMed ID: 22631065
[TBL] [Abstract][Full Text] [Related]
9. Use of everolimus in de novo renal recipients: initial experience in the Greek population.
Papanikolaou V; Vrochides D; Margari P; Imvrios G; Papagiannis A; Giakoustidis D; Fouzas I; Antoniadis N; Ouzounidis N; Ntinas A; Vergoulas G; Miserlis G; Solonaki F; Takoudas D
Transplant Proc; 2008 Nov; 40(9):3166-9. PubMed ID: 19010223
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
11. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
Sheshgiri R; Gustafsson F; Sheedy J; Rao V; Ross HJ; Delgado DH
J Heart Lung Transplant; 2009 Nov; 28(11):1193-7. PubMed ID: 19783164
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation.
Lyster H; Panicker G; Leaver N; Banner NR
Transplant Proc; 2004 Dec; 36(10):3167-70. PubMed ID: 15686720
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
14. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience.
Boffini M; Sansone F; Patanè F; Bonato R; Ribezzo M; Iacovino C; Comoglio C; Rinaldi M
Transplant Proc; 2009 May; 41(4):1349-52. PubMed ID: 19460557
[TBL] [Abstract][Full Text] [Related]
15. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy.
Sánchez-Brotons JA; Sobrino-Márquez JM; Lage-Gallé E; Romero-Rodriguez N; Guisado A; Jiménez-Díaz J; Benezet-Mazuecos J; Arizón-Muñoz JM; Mogollón MV; Martínez A
Transplant Proc; 2008 Nov; 40(9):3046-8. PubMed ID: 19010188
[TBL] [Abstract][Full Text] [Related]
16. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
17. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R
Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971
[TBL] [Abstract][Full Text] [Related]
19. The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
Nashan B
Transplant Proc; 2001; 33(7-8):3215-20. PubMed ID: 11750380
[No Abstract] [Full Text] [Related]
20. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
